Calliditas Therapeutics (CALT)
(Delayed Data from NSDQ)
$38.26 USD
-0.25 (-0.64%)
Updated Jul 24, 2024 03:52 PM ET
After-Market: $38.50 +0.25 (0.64%) 6:28 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
CALT 38.26 -0.25(-0.64%)
Will CALT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CALT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CALT
Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
CALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study
Calliditas Therapeutics AB Sponsored ADR (CALT) Surges 16.1%: Is This an Indication of Further Gains?
Calliditas (CALT) Up as sNDA for Tarpeyo Gets Priority Review
Other News for CALT
Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas provides setanaxib patent update
Calliditas Therapeutics announces USPTO issues patent for setanaxib
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
Calliditas Therapeutics’ Annual Meeting Highlights